Multivariate analysis of variables associated with 1 year RRP
| OR | 95% CI | p Value | |
|---|---|---|---|
| Model 1: assessing anti-CCP2 AUC 0.6496 (95% CI 0.5979 to 0.7003) | |||
| Anti-CCP2 positivity | 2.15 | 1.43 to 3.21 | <0.001 |
| CRP level (>10 mg/L) | 1.73 | 1.15 to 2.58 | 0.007 |
| Erosions at baseline | 1.50 | 1.00 to 2.25 | 0.049 |
| Model 2: assessing anti-MCV AUC 0.6304 (95% CI 0.5784 to 0.6825) | |||
| Anti-MCV positivity | Discarded during logistic regression | ||
| RF positivity | 2.12 | 1.40 to 3.20 | <0.001 |
| CRP level (>10 mg/L) | 1.80 | 1.21 to 2.67 | 0.004 |
| Model 3: assessing AhFibA AUC 0.6536 (95% CI 0.6018 to 0.7055) | |||
| AhFibA positivity | 2.39 | 1.57 to 3.63 | <0.001 |
| CRP level (>10 mg/L) | 1.68 | 1.13 to 2.51 | 0.011 |
| Age at RA onset | 1.02 | 1.00 to 1.04 | 0.031 |
| Model 4: assessing high ACPA titre (>3N) AUC 0.6480 (95% CI 0.5958 to 0.7003) | |||
| High anti-CCP2 or AhFibA titres | Discarded during logistic regression | ||
| High anti-MCV titres | 2.17 | 1.45 to 3.24 | <0.001 |
| CRP level (>10 mg/L) | 1.69 | 1.13 to 2.53 | 0.010 |
| Erosions at baseline | 1.50 | 1.00 to 2.25 | 0.049 |
Models included baseline ACPA status, age, erosive status, CRP level and RF status.
ACPA, anticitrullinated peptide antibodies; AhFibA, antihuman citrullinated fibrinogen antibodies; anti-CCP2, anticyclic citrullinated peptides generation 2 antibodies; anti-MCV, antimutated citrullinated vimentine antibodies; AUC, area under (the receiver operating characteristic) curve; CRP, C reactive protein; RA, rheumatoid arthritis; RF, rheumatoid factor; RRP, rapid radiographic progression.